SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending amid community excitement over potential gains and a possible deviation from Bitcoin's price action. Discussions include speculation about an ETF, share buybacks, and the start of altcoin season. Some believe LTC is undervalued and poised for a significant breakout.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as traders discuss potential breakouts and Elon Musk's influence, while some express concerns about its long-term potential. Community members are actively debating technical indicators and the possibility of a pump, with some speculating on future price movements. The conversation also includes general sentiment around crypto and altcoins.

Marathon Petroleum Corp. engages in the refining, marketing, and transportation of petroleum products. It operates through the Refining and Marketing, and Midstream segments. The Refining and Marketing segment includes refining crude oil and other feedstocks, purchasing ethanol, and refined products for resale and distribution of refined products. The Midstream segment refers to transportation, storing, distribution, and marketing of crude oil and refined products. The company was founded in 1887 and is headquartered in Findlay, OH.

Marathon Petroleum Corp

Marathon Petroleum (MPC) is gaining attention as analysts update ratings and price targets, influenced by factors such as refining margins, potential mergers, and market conditions. Community discussions revolve around technical indicators, entry and exit strategies, and potential upside amid sector-wide movements. Several options alerts are highlighting call and put opportunities, reflecting varied sentiments around MPC's future performance.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as community members discuss its recent price surge and potential for further gains, with some eyeing $1000. The excitement seems linked to increased institutional interest, particularly the Winklevoss twins' investment via Cypherpunk Technologies ($CYPH), fueling speculation about ZEC's role as a privacy-focused alternative to Bitcoin.  Traders are actively debating entry points, potential targets, and whether this rally has staying power.

SPDR Series Trust - State Street SPDR Portfolio S&P 500 Growth ETF

SPDR Portfolio S&P 500 Growth ETF

SPYG is trending due to discussions around ETF rotations, particularly between growth and dividend ETFs, and its performance relative to value and small-cap ETFs. Community members are weighing SPYG's growth potential against dividend-focused strategies and broader market trends. Recent large-cap growth strength has further fueled the conversation.

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Advanced Visualization Solutions segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GE HealthCare Technologies Inc

GEHC is trending as investors digest recent news, including potential undervaluation and upcoming conference presentations. The community is actively discussing its oversold RSI and potential for a bullish reversal, with some eyeing specific entry and target points. Bullish analysts point to Jeffries' upgrade while bears are taking a cautious view, citing valuation relative to sales.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions around the potential release of Epstein files and their implications for Trump, with community members debating the validity and impact of these files. The stock's performance is also being scrutinized, with bearish sentiment fueled by low revenue, sustained losses, and reliance on Trump's name rather than business fundamentals. Some investors express concerns about potential insider selling and the company's long-term viability.

Wix.com Ltd. operates a cloud-based website design and development platform. It offers web templates, web editor, web builder, search engine optimization tools, logo maker, web hosting, and electronic mail marketing services. The company was founded by Avishai Abrahami, Nadav Abrahami, and Giora Kaplan on October 5, 2006, and is headquartered in Tel Aviv, Israel.

Wix.com Ltd

Wix is trending as the company's earnings approach, with community members weighing whether the stock is poised for a recovery or if they've gotten in too early. Bullish sentiment is fueled by strategic partnerships, AI-driven product discovery, and recent acquisitions, while others express concerns about market share and potential AI disruption to Wix's business model. Some traders note basing patterns and look for breakouts while also acknowledging potential resistance overhead.

BlockDAG

BlockDAG (BDAG) is trending amid discussions about its ongoing presale and future launch, with debates focusing on the project's legitimacy, extended presale timeline, and potential for returns. Community members are weighing the risks and opportunities, while also sharing referral codes for the BlockDAG X1 mining app. Partnerships with Formula 1 teams and listings on crypto exchanges are adding to the buzz.

Kinder Morgan, Inc. engages in providing pipeline transportation of natural gas services. It operates through the following business segments: Natural Gas Pipelines, Products Pipelines, Terminals, and CO2. The Natural Gas Pipelines segment operates major interstate and intrastate natural gas pipelines and storage systems. The Products Pipelines segment is involved in the operation of refined petroleum products, crude oil, and condensate pipelines. The Terminals segment includes the operation of liquids and bulk terminal facilities that store and handle various commodities. The CO2 segment produces, transports, and markets to oil fields that use CO2 as a flooding medium to increase recovery and production of crude oil from mature oil fields. The company was founded by Richard D. Kinder and William V. Morgan in February 1997 and is headquartered in Houston, TX.

Kinder Morgan Inc - Ordinary Shares - Class P

Kinder Morgan is trending amid analyst upgrades and discussions around its potential to benefit from increased natural gas demand, particularly from AI data centers. Community members are weighing KMI against competitors, focusing on dividend stability and growth prospects. The stock's recent performance and infrastructure projects are also key talking points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

Groupon, BriaCell Therapeutics, and InnovAge shine as Zacks' top November picks for powerful earnings acceleration potential.

Top 3 Earnings Acceleration Buys for November 

Groupon, BriaCell Therapeutics and InnovAge stand out with accelerating earnings momentum as November's market optimism approaches. 

All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy

BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Shares of BriaCell Therapeutics Corp (BCTX) fell over 8% in Thursday's after-hours trading as the Canadian biotech firm priced a public offering of about $13.8 million.&nbsp;Retail investors, however, were focused on positive catalysts from earlier in the day.The West Vancouver, Canada-based company said it is issuing over 3 million shares at $4.50 apiece, more than 25% lower from the last closing price.The offer includes nearly 400,000 units sold through the full exercise of the underwriter's option.Each unit has one common share (or a pre-funded warrant) and one tradeable warrant.&nbsp;BriaCell expects to close the offering on April 28, pending customary closing conditions, and will use the proceeds for working capital, corporate purposes, and advancing its immunotherapy programs.Earlier on Thursday, BriaCell said that a patient in its Phase 1/2a Bria-OTS trial continues to show a complete resolution of lung metastasis, first reported in February 2025, now confirmed at the four-month mark. The news sent the stock up more than 11% in the regular session.The 78-year-old woman with metastatic breast cancer had previously&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bctx-stock-climbs-after-bria-ots-resolves-cancer-metastasis/chPYRuVRAQ">failed</a> several lines of therapy and received the lowest dose level in the study.Upon enrollment in November 2024, the patient had widespread disease, including lung, lymph node, and bone metastases.&nbsp;After receiving Bria-OTS injections every two weeks for six weeks, then every three weeks, her lung metastasis fully resolved, and stable disease has been maintained elsewhere in the body.On Stocktwits, the clinical news took precedence as sentiment for BriaCell turned even more 'extremely bullish' late Thursday amid a 1,266% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/BCTX_sentiment_and_message_volume_as_of_April_24_png_c4da18642c.webp" alt="BCTX sentiment and message volume as of April 24.png" width="1318" height="316"><figcaption>BCTX sentiment and message volume as of April 24. | source: Stocktwits</figcaption></figure>"This is THE most undervalued biotech on NASDAQ, and that will be proven in coming months," posted one user.<stembedurl>https://stocktwits.com/Fvalstounge/message/612629738</stembedurl>"This company should be worth several billion dollars... WOW," wrote another.<stembedurl>https://stocktwits.com/Hannibal_Smith/message/61253769</stembedurl>BriaCell stock, however, has lost over 82% in the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone

Earlier on Thursday, BriaCell said that a patient in its Phase 1/2a Bria-OTS trial continues to show a complete resolution of lung metastasis.

Equity

Earlier on Thursday, BriaCell said that a patient in its Phase 1/2a Bria-OTS trial continues to show a complete resolution of lung metastasis.


Nasdaq-listed shares of BriaCell Therapeutics Corp. (BCTX) traded nearly 12% higher on Wednesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6008109823653589&amp;symbol=BCTX">announced</a> positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors (CPI).The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients.The survival data of patients enrolled in the study with hormone receptor-positive (HR+) metastatic breast cancer exceeds those of patients treated with the prescription medicine Trodelvy, the company said.HR+ metastatic breast cancer patients treated with Bria-IMT plus check point inhibitors had a median overall survival of 17.3 months, exceeding the 14.4 months with Trodelvy in similar heavily pre-treated patients.In patients with triple negative breast cancer, the survival data was similar to patients on Trodelvy but still 70% higher than those of chemotherapy, the company said.CEO William V Williams expressed optimism about the survival benefit data.“Bria-IMT appears to be very well-tolerated,” he said, adding that the company looks forward to confirming the data in its Phase 3 study.Patients with HR+ and TNBC metastatic breast cancer have an overall survival of only a few months and limited therapeutic options.Earlier this month, BriaCell’s majority-owned subsidiary BriaPro Therapeutics Corp announced that it is developing antibodies to B7-H3, a key player in cancer progression, using molecular modeling techniques.On Stocktwits, retail sentiment around BriaCell Therapeutics rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’.<figure class="image"><img style="aspect-ratio:1298/304;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_16_at_12_16_46_PM_png_18e64dcd73.webp" alt="BCTX's Sentiment Meter and Message Volume as of 12:15 p.m. ET on April 16, 2025 | Source: Stocktwits" width="1298" height="304"><figcaption>BCTX's Sentiment Meter and Message Volume as of 12:15 p.m. ET on April 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/BCTX">BCTX stock</a> is down by about 52% year-to-date and by about 88% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/icad-stock-soars-merger-announcement-with-radnet/chQPV8HRbOq">iCAD Stock Rockets On Merger Announcement With RadNet: Retail’s Elated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

BriaCell Stock Rises On Positive Survival Data From Study In Cancer Patients: Retail Gets More Bullish

HR+ metastatic breast cancer patients treated with Bria-IMT plus check point inhibitors had a median overall survival of 17.3 months, exceeding the 14.4 months with Trodelvy in similar heavily pre-treated patients, the company said. 

Shares of BriaCell Therapeutics Corp. rose nearly 2% on Monday afternoon, reversing earlier losses as traders reacted to promising clinical data. Trading volume surged to over 90 times the daily average of about 146,000 shares.BriaCell announced what it called an “unprecedented clinical response,” including the complete resolution of a lung metastasis in a patient with metastatic breast cancer.&nbsp;The patient, a 78-year-old woman who had failed multiple prior treatments, was the first to receive Bria-OTS, a personalized off-the-shelf immunotherapy currently being tested in a Phase 1/2a dose escalation study.At the time of enrollment on Nov. 21, 2024, she had extensive metastases, including multiple bone, lymph node, and lung lesions, according to the company.&nbsp;After receiving four Bria-OTS injections over two weeks, her lung metastasis completely disappeared, while the disease remained stable elsewhere, BriaCell said.Bria-OTS is a next-generation, personalized advancement of BriaCell’s lead candidate, Bria-IMT, which is currently in a pivotal Phase 3 study for metastatic breast cancer.By Monday afternoon, BriaCell was among the top trending tickers on Stocktwits, with the retail messages largely optimistic.“The data on this patient is a true game changer,” wrote one trader, alleging that earlier weakness in the stock was due to short-seller manipulation.<stembedurl>https://stocktwits.com/JJBurch/message/602660557</stembedurl>Traders also noted that H.C. Wainwright more than doubled its price target on BriaCell to $32, implying a nearly 700% upside from current levels.<stembedurl>https://stocktwits.com/Jaymes11/message/602663519</stembedurl>Despite Monday’s gains, BriaCell shares remain down over 90% in the past year. Message volume on Stocktwits has more than tripled in that period, reflecting growing retail interest.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

BriaCell Stock Climbs After ‘Unprecedented’ Immunotherapy Response In Breast Cancer Patient, Retail Exudes Optimism

Bria-OTS is a next-generation, personalized advancement of BriaCell’s lead candidate, Bria-IMT, which is currently in a pivotal Phase 3 study for metastatic breast cancer.

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters.&nbsp;Our focus is on quality, liquid, growth-oriented, and under-followed companies in sectors actively drawing in capital such as AI, blockchain, biotech and consumer.&nbsp;This real-time news surveillance and targeting combined with our proprietary 5-point analysis, aids in uncovering stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.&nbsp;Here’s what we’re keeping our eyes on:<h3>1. Purple Biotech (NASDAQ: PPBT)</h3>Background: Purple Biotech is a clinical-stage oncology company that aims to redefine cancer treatment through its innovative approaches targeting tumor immune evasion and drug resistance. Its lead product, CM24, is a first-in-class anti-CEACAM1 antibody being developed to treat pancreatic and other aggressive cancers. The oncology space, worth billions, continues to see intense investor interest, especially as companies explore biomarker-driven therapies.The News: Purple Biotech unveiled final Phase 2 results showing CM24 combined with nivolumab and chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in pancreatic cancer patients with specific biomarkers. The data revealed a 79% reduction in death risk and a 5.1-month OS improvement, particularly in biomarker-enriched patient groups.What It Means: These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing potential.Stock Reaction: PPBT skyrocketed 151%, reflecting the market’s recognition of this major milestone in the fight against pancreatic cancer.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_23_40_AM_19763a2e26.png" alt="Screenshot 2024-12-05 at 2.23.40 AM.png">&nbsp;<hr>&nbsp;<h3>2. Stereotaxis (NYSE: STXS)</h3>Background: Stereotaxis is at the forefront of surgical robotics, specializing in robotic magnetic navigation (RMN) systems for minimally invasive endovascular interventions. Its GenesisX system aims to improve precision, safety, and efficiency in procedures, a critical innovation as the global market for robotic-assisted surgeries is projected to grow at a double-digit CAGR over the next decade.The News: The GenesisX robotic system was showcased for the first time at the RSNA 2024 Annual Meeting, in collaboration with Neusoft Medical Systems. The partnership aligns GenesisX with advanced imaging technologies, offering enhanced capabilities for healthcare providers worldwide.What It Means: The exposure at RSNA, one of the largest radiology conferences globally, strengthens Stereotaxis' visibility and positions the GenesisX as a next-generation tool for minimally invasive surgeries. This partnership could unlock new revenue streams as the healthcare sector increasingly adopts robotic solutions.Stock Reaction: STXS edged up 4.18%, with investors optimistic about the long-term implications of the GenesisX system.Stocktwits.com Sentiment &amp; Popularity:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_25_09_AM_6fecf5b145.png" alt="Screenshot 2024-12-05 at 2.25.09 AM.png">&nbsp;<hr>&nbsp;<h3>3. Delcath Systems (NASDAQ: DCTH)</h3>Background: Delcath Systems focuses on innovative therapies for primary and metastatic liver cancers. Its flagship product, HEPZATO KIT™, offers a unique approach to delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure. This precision is critical for targeting liver-dominant diseases—a market that represents tens of thousands of patients annually.The News: The FDA has cleared Delcath’s Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer. The study will compare HEPZATO plus standard chemotherapy with chemotherapy alone, aiming to validate its safety and efficacy in this high-need population.What It Means: HEPZATO has already shown promise in metastatic uveal melanoma, and this expansion could significantly broaden its market reach. The ability to address liver-dominant cancers positions Delcath as a potential leader in a niche but high-value market.Stock Reaction: DCTH rose 6.4% on the day, continuing its strong performance following a 203% year-to-date rally.&nbsp;&nbsp;<hr>&nbsp;<h3>4. BrainStorm Cell Therapeutics (NASDAQ: BCLI)</h3>Background: BrainStorm is a pioneering biotech company developing autologous adult stem cell therapies for neurodegenerative diseases like ALS and progressive MS. Its lead candidate, NurOwn®, is designed to deliver neurotrophic factors directly to damaged neurons, potentially altering the course of these debilitating diseases. With few effective therapies for ALS, the market is ripe for disruptive innovation.The News: BrainStorm announced a December 11 webinar featuring updates on its Phase 3b trial of NurOwn, aimed at refining the therapy’s efficacy for FDA approval. This comes as the company prepares for a pivotal registrational trial.What It Means: If successful, NurOwn could be the first significant breakthrough for ALS in years, addressing an unmet medical need in a multibillion-dollar market. The company’s focus on early-stage ALS patients may improve trial outcomes and strengthen its case for regulatory approval.Stock Reaction: BCLI dipped 2.66%, reflecting cautious investor sentiment as the market awaits trial data.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_26_15_AM_28681ca8de.png" alt="Screenshot 2024-12-05 at 2.26.15 AM.png">&nbsp;<hr>&nbsp;<h3>5. DMG Blockchain Solutions (OTCQB: DMGGF)</h3>Background: DMG Blockchain integrates Bitcoin mining with sustainability and AI-driven data centers. Its Terra Pool initiative is designed to create a carbon-neutral Bitcoin mining ecosystem, catering to ESG-conscious investors and industries. With institutional adoption of Bitcoin accelerating, DMG’s dual focus on growth and environmental responsibility makes it a standout.The News: DMG reported November mining results of 32 BTC, an increased hashrate of 1.66 EH/s, and significant insider purchases by its CEO and COO. The company also secured $17.3 million to fund growth initiatives, including AI and blockchain infrastructure.What It Means: The raised capital and insider purchases signal confidence in DMG’s ability to scale operations and align with Bitcoin’s anticipated market growth. The focus on sustainability could attract institutional players prioritizing ESG compliance.Stock Reaction: DMGI remained stable dipping just slightly, with the market digesting the long-term growth potential from recent investments.&nbsp;<hr>&nbsp;<h3>6. BriaCell Therapeutics (NASDAQ: BCTX)</h3>Background: BriaCell specializes in novel immunotherapies targeting advanced breast cancer. Its lead therapy, Bria-IMT™, is designed to boost the immune system's response against tumors. With metastatic breast cancer affecting over 2 million women globally, there’s an urgent need for effective treatments.The News: BriaCell’s pivotal Phase 3 study of Bria-IMT received a positive safety review from the DSMB, allowing the trial to proceed without changes. The trial is being conducted under the FDA’s Fast Track Designation.What It Means: The DSMB’s approval reinforces Bria-IMT’s safety and paves the way for the company to potentially deliver a game-changing therapy for metastatic breast cancer patients. The Fast Track Designation further emphasizes its potential impact.Stock Reaction: BCTX shares soared 13%, reflecting growing investor confidence in the company’s clinical progress.Rumours from Twitter:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_27_31_AM_e685b0a306.png" alt="Screenshot 2024-12-05 at 2.27.31 AM.png">&nbsp;&nbsp;<h3>7. Laser Photonics Corporation (NASDAQ: LASE)</h3>Background: Laser Photonics Corporation specializes in industrial laser systems, providing innovative solutions for cleaning, material processing, and now pharmaceuticals. With its recent acquisition of Control Micro Systems, Inc., the company is expanding into new sectors, including the fast-growing pharmaceutical and semiconductor industries. The industrial laser market, driven by advances in automation and precision engineering, is projected to exceed $10 billion by 2030, making it a hotbed for innovation.The News: Laser Photonics announced the successful installation of a state-of-the-art pill drilling system at a customer’s facility. The system, a Class I automated CO2 laser with advanced fume extraction and machine vision inspection, is designed to streamline pill production processes. This system also doubles as an anti-counterfeiting solution, addressing critical challenges in the pharmaceutical supply chain.What It Means: This installation signifies Laser Photonics’ pivot into high-demand verticals like pharmaceuticals. By integrating advanced laser technology with automated inspection, the company is positioning itself as a key supplier in a market prioritizing efficiency, precision, and security.Stock Reaction: LASE shares declined 6.40%, reflecting broader market volatility rather than company-specific concerns. Investors appear cautiously optimistic about the company's potential in its newly targeted markets.&nbsp;Also Read:<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/why-this-small-biotech-stock-could-be-primed-for-a-breakout/">&nbsp;Why This Small Biotech Stock Could Be Primed for a Breakout</a>Be the First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like&nbsp;AST SpaceMobile (NASDAQ: ASTS), which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend PR Newswire VANCOUVER, BC, Dec. 2, 2024 USA...

Why Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On Wednesday

BriaCell Therapeutics stock rises on positive Phase 2 trial results showing improved survival in late-stage metastatic breast cancer patients treated with Bria-IMT and an immune checkpoint...

Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Drops By 7.9%

BriaCell Therapeutics Corp. (NASDAQ:BCTX - Get Free Report) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling...

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$3.28	--	--	N/A
Q4 '25	-$12.11	--	--	N/A
Q3 '25	-$1.76	-$16.40	-831.82%	MISSED
Q2 '25	-$29.10	-$2.33	91.99%	BEAT
Q1 '25	-$0.08	--	--	N/A

BCTX
BriaCell Therapeutics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest BCTX News

BCTXBriaCell Therapeutics Corp